InMed Pharmaceuticals is a biopharmaceutical company developing small molecule drug candidates that target endocannabinoid CB1 and CB2 receptors to treat neurological and ophthalmological diseases with high unmet medical needs, including Alzheimer's disease, age-related macular degeneration, and epidermolysis bullosa. Through its subsidiary BayMedica, the company also manufactures and sells bulk rare non-intoxicating cannabinoids as business-to-business ingredients to companies in the health and wellness, nutraceutical, cosmetics, and functional food sectors. The pharmaceutical candidates are in preclinical and clinical development stages with no approved products, while the cannabinoid ingredient business generates revenue through direct sales of manufactured cannabinoids to commercial distributors and manufacturers, leveraging the company's proprietary manufacturing capabilities and market position as an early-mover supplier in the rare cannabinoid space.